Loading...
Etanercept biosimilars
Etanercept was the first tumour necrosis factor alpha antagonist approved in the USA for the treatment of rheumatoid arthritis, in 1998, and then for other diseases. With the etanercept patent set to expire in the EU in 2015, a number of etanercept copies have reached the production phase and are un...
Saved in:
| Published in: | Rheumatol Int |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Springer Berlin Heidelberg
2014
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4308636/ https://ncbi.nlm.nih.gov/pubmed/24980068 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00296-014-3080-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|